Participating at the Society of Interventional Oncology Conference Will Allow the Company to Share Practical Insights and Personal ExperiencesHINGHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it is attending the Society of Interventional Oncology (SIO) annual meeting, being held in Savannah, GA, February 4-8, 2026. The timing of the conference, which is during the Company’s ...

Core Insights - Microbot Medical (MBOT) is a robotic medical technology company that has developed LIBERTY, the world's first single-use remotely-operated robotic technology for endovascular interventions, which facilitates minimally invasive procedures and reduces radiation exposure [1] Company Overview - Microbot Medical specializes in robotic medical technology, focusing on innovations that enhance the efficiency and safety of medical procedures [1] Product Development - The LIBERTY system represents a significant advancement in the field of endovascular interventions, allowing for streamlined processes that minimize patient risk and improve outcomes [1]

Limited Market Release (LMR) of the LIBERTY® System is on Schedule Building on Positive Customer Feedback and Growing Market Enthusiasm, the Company Prepares for Full Market Release (FMR) in Q2 HINGHAM, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, is continuing to generate significant market and new customer momentum as it enters 2026. In 2025, the Company met its milestones, including several ...

Core Insights - Emory University Hospital has become the first hospital to adopt the LIBERTY Endovascular Robotic System, aligning with its commitment to advancing interventional radiology [1][5] - LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, designed to enhance precision and reduce radiation exposure [2][6] - Microbot Medical is collaborating with Emory to establish an Endovascular Robotics Program, aiming to improve patient care in various peripheral intervention procedures [1][3] Company Overview - Microbot Medical Inc. is focused on transforming endovascular procedures through advanced robotic technology, with LIBERTY being the first FDA-cleared single-use robotic solution [6] - The company emphasizes innovation and has a strong intellectual property portfolio, positioning itself as a leader in the future of endovascular care [6] Market Strategy - The limited market release of LIBERTY has commenced, with plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026 [2] - The adoption of LIBERTY is seen as a significant milestone in the surgical robotic space, reflecting years of dedication and progress by the Microbot team [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ Commission file number: 000-19871 MICROBOT MEDICAL INC. Indicate by check whether the registrant: (1) has filed all reports required to be fi ...

Core Insights - Microbot Medical Inc. has announced the commercial availability of its LIBERTY® Endovascular Robotic System in the U.S. following FDA clearance, marking a significant milestone in the introduction of single-use robotic systems for peripheral endovascular procedures [1][2] - The Limited Market Release (LMR) will focus on high procedure volume regions to gather real-world insights and prepare for a Full Market Release (FMR) expected at the Society of Interventional Radiology meeting in April 2026 [1][2] Company Developments - The company has established a core commercial team and secured a third-party logistics partner to support the LMR of LIBERTY® [2] - Positive feedback from physicians and hospital administrators has validated the decision to proceed with the limited market release [1][2] Product Overview - LIBERTY® is the first FDA cleared single-use, remotely operated robotic system designed for precision, efficiency, and safety in endovascular procedures [3] - The product is backed by a strong intellectual property portfolio and a commitment to innovation, positioning Microbot Medical as a leader in the endovascular care market [3]

Core Insights - Microbot Medical Inc. is set to exhibit its LIBERTY Endovascular Robotic System at the upcoming Symposium on Clinical Interventional Oncology, marking its first commercial presence post-FDA clearance [1][2] - The company has completed the recruitment of its commercial leadership team in preparation for the limited market launch of the LIBERTY System, expected in Q4 of this year [2][6] Company Developments - The LIBERTY System will be showcased at booth 208, where interventional oncologists can schedule live hands-on demonstrations [2] - Justin Bourne has joined as Regional Sales Director, bringing 20 years of experience in sales leadership within the healthcare industry, previously at Boston Scientific [3] - Dani Kulp has been appointed as Sales Training Director, with over 15 years of experience in medical education and sales training, focusing on endovascular therapies [4] - Xiomara Ortiz has taken on the role of Marketing Communications Manager, leveraging her extensive experience in digital marketing and brand strategy to enhance the company's brand presence [5] Strategic Outlook - The company has secured a logistics partner and is preparing for the limited market launch of the LIBERTY System, indicating strong momentum since receiving FDA clearance [6] - The addition of key commercial team members is aimed at building a solid foundation for both immediate launch plans and long-term commercial strategy [6] Company Background - Microbot Medical Inc. focuses on transforming endovascular procedures through advanced robotic technology, with the LIBERTY System being the first single-use, remotely operated robotic solution designed for precision and safety [7]

Core Insights - Microbot Medical Inc. is set to launch its LIBERTY Endovascular Robotic System in Q4 2025, with a broader release planned for April 2026 during a major conference [1][4] Group 1: Company Overview - Microbot Medical Inc. specializes in innovative medical devices, focusing on transforming endovascular procedures through advanced robotic technology [4] - The LIBERTY System is the first single-use, remotely operated robotic solution designed for precision, efficiency, and safety [4] Group 2: Partnership and Logistics - The company has partnered with a U.S.-based third-party logistics (3PL) provider to support the commercialization of the LIBERTY System, ensuring effective inventory management and customer support [1][2] - The 3PL provider specializes in the medical device industry, allowing the company to leverage its proximity to key markets and maintain inventory in a climate-controlled warehouse [2] Group 3: Operational Strategy - The partnership with an established logistics provider is expected to enhance the company's go-to-market initiatives, making the commercial launch of LIBERTY more efficient [3]

Core Points - Microbot Medical Inc. announced the third and final closing of its preferred investment options, resulting in the issuance of 13,989,115 shares of common stock [1][4] - The total gross proceeds from the three closings amounted to approximately $29.2 million, with potential additional proceeds of about $63 million from the exercise of short-term preferred investment options [4] Group 1: Investment Details - The first closing generated approximately $25.2 million from the exercise of options for 12,064,627 shares at prices ranging from $1.50 to $2.13 per share [2][4] - The second closing brought in approximately $1.2 million for 600,000 shares at an exercise price of $2.10 per share [2][4] - The third closing resulted in approximately $2.8 million for 1,324,488 shares at an exercise price of $2.10 per share [2][4] Group 2: Future Plans and Use of Proceeds - The company plans to utilize the net proceeds for the development, commercialization, and regulatory activities of its LIBERTY Robotic System, potential acquisitions, and general corporate purposes [4] - The new short-term series J preferred investment options will have an exercise price of $4.50 per share and will be exercisable six months after issuance [2][4] Group 3: Company Overview - Microbot Medical Inc. is focused on transforming endovascular procedures through advanced robotic technology, with its LIBERTY Endovascular Robotic System being a key product [7][8] - The company is backed by a strong intellectual property portfolio and is committed to innovation in endovascular care [8]

Core Insights - Microbot Medical Inc. has received its first patent in Japan for the LIBERTY® Endovascular Robotic System, enhancing its intellectual property portfolio [1] - The U.S. FDA granted marketing clearance for the LIBERTY® System on September 8, 2025, prompting the company to accelerate its commercial launch plans targeting 2.5 million peripheral endovascular procedures annually in the U.S. [2] - The company is focusing on the U.S. market while exploring opportunities in other global markets, particularly Japan, which may expedite local approval and adoption of its technology [3] Company Overview - Microbot Medical Inc. is a medical device company specializing in advanced robotic technology aimed at transforming endovascular procedures [3] - The LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency, and provider safety [3] - The company is committed to innovation and has a strong intellectual property portfolio to support its growth [3]